Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification

Neuroblastomas (NBs) exhibit heterogeneity and show clinically significant prognosis classified by genetic alterations. Among prognostic genes or genome factors, MYCN amplification (MNA) is the most established genomic marker of poor prognosis in patients with NB. However, the prognostic classificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yanna, Jin, Yan, Yu, Jinpu, Wang, Jingfu, Qiu, Yanli, Duan, Xiaofeng, Ye, Yingnan, Cheng, Yanan, Dong, Li, Feng, Xiaolong, Wang, Daowei, Li, Zhongyuan, Tian, Xiangdong, Wang, Huijuan, Yan, Jie, Zhao, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564799/
https://www.ncbi.nlm.nih.gov/pubmed/28591696
http://dx.doi.org/10.18632/oncotarget.17917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564799/
https://www.ncbi.nlm.nih.gov/pubmed/28591696
http://dx.doi.org/10.18632/oncotarget.17917

Ejemplares similares